Thermo Fisher Scientific Human VEGF-165, Animal-Free Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Western Blot (WB)

-

View 1 publication 1 publication

ELISA (ELISA)

-

View 1 publication 1 publication

Functional Assay (Functional)

Assay-dependent

-

In vitro Assay (IV)

-

View 29 publications 29 publications

Miscellaneous PubMed (Misc)

-

View 7 publications 7 publications

Product Specifications

Species

Human

Published species

Bovine, Dog, Human, Mouse, Pig, Rabbit, Rat, Sheep

Expression System

E. coli

Amino acid sequence

APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR

Molecular weight

38.2 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<0.1 EU/µg

Activity

Determined by its ability to stimulate the proliferation of human umbilical vein endothelial cells (HUVEC). The expected ED50 for this effect is 1.0-10.0ng/ml.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

Recombinant Human VEGF 165 is a 38.2 kDa, disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.